OncoMatch/Clinical Trials/NCT06361888

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Is NCT06361888 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine and Nab-paclitaxel Plus Gemcitabine for metastatic pancreatic cancer.

Phase 2/3RecruitingHutchmedNCT06361888Data as of May 2026

Treatment: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine · Nab-paclitaxel Plus Gemcitabine · Surufatinib with Nab-paclitaxel, and Gemcitabine — To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Disease stage

Required: Stage IV

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: systematic anti-tumor therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify